HPV vaccination coverage in the federal state of Belgium according to regions and their impact

Long-term results of the HPV vaccination programs in Australia and Scotland have shown a tremendous impact on the reduction of HPV infection rates and precancerous diseases. Both countries started mass vaccination ten years (Australia) and eight years (Scotland) ago and achieved a vaccination covera...

Full description

Saved in:
Bibliographic Details
Published inFacts, views & vision in ObGyn Vol. 10; no. 2; pp. 101 - 105
Main Authors Tjalma, Waa, Brasseur, C, Top, G, Ribesse, N, Morales, I, Van Damme, P A
Format Journal Article
LanguageEnglish
Published Belgium Universa Press 01.06.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Long-term results of the HPV vaccination programs in Australia and Scotland have shown a tremendous impact on the reduction of HPV infection rates and precancerous diseases. Both countries started mass vaccination ten years (Australia) and eight years (Scotland) ago and achieved a vaccination coverage of more than 80 %. Within 20 to 30 years a reduction in cervical cancer by more than 75 % is expected. Furthermore, there will be a reduction in other HPV related cancers like vaginal, vulva, perineal, anal and oropharyngeal cancers. In order to be successful, a high vaccination coverage is needed. In Belgium, the vaccination was introduced in 2010 in the Flemish community and in 2011 in the French community. In the first vaccinated cohorts the coverage in Flemish and French Communities was respectively 84% (2010) and 29% (2012-2013). The latest data suggest that the Flemish Community (Flanders Region) attained a coverage of 91 % while the French Community (Walloon Region) attained a coverage of around 36 %. The regional difference in coverage offers a real-life case. The worst-case scenario could end up with proportionally one half of country having more HPV related cancers than the other half. Currently efforts are performed to increase the coverage rates in both regions and consequently decreasing this difference. Additionally, the updated recommendations regarding the HPV vaccination by the Belgian NITAG (National Immunization Technical Advisory Group) stated that the HPV vaccination should be gender neutral. This could stimulate the vaccination program and increase the coverage. The coverage rate in Flanders is among the highest in the world and the rate in the French Community is increasing. Efforts should be continued in order to maintain trust and increase the coverage rate.
AbstractList Long-term results of the HPV vaccination programs in Australia and Scotland have shown a tremendous impact on the reduction of HPV infection rates and precancerous diseases. Both countries started mass vaccination ten years (Australia) and eight years (Scotland) ago and achieved a vaccination coverage of more than 80 %. Within 20 to 30 years a reduction in cervical cancer by more than 75 % is expected. Furthermore, there will be a reduction in other HPV related cancers like vaginal, vulva, perineal, anal and oropharyngeal cancers. In order to be successful, a high vaccination coverage is needed. In Belgium, the vaccination was introduced in 2010 in the Flemish community and in 2011 in the French community. In the first vaccinated cohorts the coverage in Flemish and French Communities was respectively 84% (2010) and 29% (2012-2013). The latest data suggest that the Flemish Community (Flanders Region) attained a coverage of 91 % while the French Community (Walloon Region) attained a coverage of around 36 %. The regional difference in coverage offers a real-life case. The worst-case scenario could end up with proportionally one half of country having more HPV related cancers than the other half. Currently efforts are performed to increase the coverage rates in both regions and consequently decreasing this difference. Additionally, the updated recommendations regarding the HPV vaccination by the Belgian NITAG (National Immunization Technical Advisory Group) stated that the HPV vaccination should be gender neutral. This could stimulate the vaccination program and increase the coverage. The coverage rate in Flanders is among the highest in the world and the rate in the French Community is increasing. Efforts should be continued in order to maintain trust and increase the coverage rate.
Long-term results of the HPV vaccination programs in Australia and Scotland have shown a tremendous impact on the reduction of HPV infection rates and precancerous diseases. Both countries started mass vaccination ten years (Australia) and eight years (Scotland) ago and achieved a vaccination coverage of more than 80 %. Within 20 to 30 years a reduction in cervical cancer by more than 75 % is expected. Furthermore, there will be a reduction in other HPV related cancers like vaginal, vulva, perineal, anal and oropharyngeal cancers. In order to be successful, a high vaccination coverage is needed. In Belgium, the vaccination was introduced in 2010 in the Flemish community and in 2011 in the French community. In the first vaccinated cohorts the coverage in Flemish and French Communities was respectively 84% (2010) and 29% (2012-2013). The latest data suggest that the Flemish Community (Flanders Region) attained a coverage of 91 % while the French Community (Walloon Region) attained a coverage of around 36 %. The regional difference in coverage offers a real-life case. The worst-case scenario could end up with proportionally one half of country having more HPV related cancers than the other half. Currently efforts are performed to increase the coverage rates in both regions and consequently decreasing this difference. Additionally, the updated recommendations regarding the HPV vaccination by the Belgian NITAG (National Immunization Technical Advisory Group) stated that the HPV vaccination should be gender neutral. This could stimulate the vaccination program and increase the coverage. The coverage rate in Flanders is among the highest in the world and the rate in the French Community is increasing. Efforts should be continued in order to maintain trust and increase the coverage rate.
Author Top, G
Morales, I
Brasseur, C
Van Damme, P A
Tjalma, Waa
Ribesse, N
Author_xml – sequence: 1
  givenname: Waa
  surname: Tjalma
  fullname: Tjalma, Waa
  organization: Multidisciplinary Breast cancer clinic, Gynaecological Oncology Unit, Department of Obstetrics & Gynaecology, Antwerp University Hospital, University of Antwerp, Wilrijkstraat 10, 2650 Antwerpen, Belgium
– sequence: 2
  givenname: C
  surname: Brasseur
  fullname: Brasseur, C
  organization: French Community, Immunization programme, Health department, Office of Birth and Childhood, Chaussée de Charleroi 95, B-1060 Bruxelles, Belgium
– sequence: 3
  givenname: G
  surname: Top
  fullname: Top, G
  organization: Infectious Disease Control and Vaccination, Flemish Agency for Care and Health, Ellipse Building, K. Albert II-laan 35, box 33, B-1030 Brussels, Belgium
– sequence: 4
  givenname: N
  surname: Ribesse
  fullname: Ribesse, N
  organization: French community, School Health Services support, Health department, Office of Birth and Childhood, Chaussée de Charleroi 95, B-1060 Bruxelles, Belgium
– sequence: 5
  givenname: I
  surname: Morales
  fullname: Morales, I
  organization: French Community, Immunization programme, Health department, Office of Birth and Childhood, Chaussée de Charleroi 95, B-1060 Bruxelles, Belgium
– sequence: 6
  givenname: P A
  surname: Van Damme
  fullname: Van Damme, P A
  organization: Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp, Campus 3 Eiken, Universiteitsplein, 1, 2610 Antwerpen, Belgium
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31110649$$D View this record in MEDLINE/PubMed
BookMark eNpVkE9LxDAQxXNYcVfdryA5einkTzdpLoIu6goLelCPljSZdiNtUpt0wW9vxVV0LsPw5v3eMCdo5oOHGVowwllGclrM0TLGNzJVQSVbqWM055RSInK1QK-bxxe818Y4r5MLHpuwh0E3gJ3HaQe4BjvNLY5JJ8ChxtfQNm7s8OQJg3W-wSngAZrJHLH29svlBuy6Xpt0ho5q3UZYHvoper69eVpvsu3D3f36apv1VImUga0YZbYugMhKUsMNl1yIXGoqFGi-spwrrShUhBqVi6oquLRVQUEywQ3hp-jym9uPVQfWgE_T0WU_uE4PH2XQrvyveLcrm7AvxYoKWsgJcHEADOF9hJjKzkUDbas9hDGWjHFGVF5wNq2e_836Dfl5Kv8EgHp13w
ContentType Journal Article
Copyright Copyright © 2018 Facts, Views & Vision
Copyright_xml – notice: Copyright © 2018 Facts, Views & Vision
DBID NPM
7X8
5PM
DatabaseName PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList PubMed

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EndPage 105
ExternalDocumentID 31110649
Genre Editorial
Commentary
GroupedDBID ADBBV
ADRAZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
DIK
EBS
EJD
HYE
KQ8
M48
NPM
OK1
PGMZT
RPM
7X8
5PM
ID FETCH-LOGICAL-p196t-edb212df8e07b71c3c3736647a169ea35d339a91eb01c946bb837db81e7263c03
IEDL.DBID RPM
ISSN 2032-0418
IngestDate Tue Sep 17 21:24:55 EDT 2024
Fri Aug 16 04:19:29 EDT 2024
Sat Sep 28 08:32:43 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 2
Keywords vaccination coverage
Flanders
Belgium
difference
Walloon Region
cervical cancer
HPV
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-p196t-edb212df8e07b71c3c3736647a169ea35d339a91eb01c946bb837db81e7263c03
Notes SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516187/
PMID 31110649
PQID 2232094832
PQPubID 23479
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6516187
proquest_miscellaneous_2232094832
pubmed_primary_31110649
PublicationCentury 2000
PublicationDate 2018-Jun
20180601
PublicationDateYYYYMMDD 2018-06-01
PublicationDate_xml – month: 06
  year: 2018
  text: 2018-Jun
PublicationDecade 2010
PublicationPlace Belgium
PublicationPlace_xml – name: Belgium
– name: Wetteren, Belgium
PublicationTitle Facts, views & vision in ObGyn
PublicationTitleAlternate Facts Views Vis Obgyn
PublicationYear 2018
Publisher Universa Press
Publisher_xml – name: Universa Press
SSID ssj0000817259
Score 2.1616843
Snippet Long-term results of the HPV vaccination programs in Australia and Scotland have shown a tremendous impact on the reduction of HPV infection rates and...
SourceID pubmedcentral
proquest
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 101
SubjectTerms Opinion Paper
Title HPV vaccination coverage in the federal state of Belgium according to regions and their impact
URI https://www.ncbi.nlm.nih.gov/pubmed/31110649
https://search.proquest.com/docview/2232094832
https://pubmed.ncbi.nlm.nih.gov/PMC6516187
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NT4MwFH_ZdjBejN_Or9TEKxtQaOGoi8tigtnBmZ0ktLRKssGizL_fRwGzGU_eIFBCXl_7fr--L4BbzrVUWriWYFpYnvZ9K9E8xatAuBq5mGuOBqInNpl5j3N_3gG_zYUxQftSZIN8sRzk2buJrVwt5bCNExtOoxHzqzLvfNiFLiroBkU322-ANtk0Sauag1u251Q9-SiuabS-fwLJ3_GQGwZmvA97DTIkd_UfHEBH5YewEzW-7yN4nUxfyFci8c5Ik8gq-hK3A5LlBGEc0VVdCPyCyREihSb3avGWrZcExyDFRBtFyoJUnRhQ00iSp8R4CUidKHkMs_HD82hiNd0RrBWumtJSqUCzk-pA2VxwR1JJOWXM44nDQpVQP6U0TEJHCduRoceEQC6aisBR3GVU2vQEenmRqzMgThAKhEVu6AmJfNINFVNaudILhWa-Svtw0wotRu2rXApJror1Z4zgwkWCiNtCH05rIcarukxG3Iq8D3xLvD8vVJWtt5_ghJsK180En_975AXsIrIJ6piuS-iVH2t1heihFNfQjbzg2ujMNw6nyaQ
link.rule.ids 230,315,730,783,787,888,2228,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDLZgSMCF92M8g8S1W9u0SXuEiWk8hjiwiRNVkyYwsXUTdBz49bjpiraJC9xapamiOrY_119sgHPOtVRauJZgWlie9n0r1jzBq0C4GmMx1_waaN-zVse7efKfFsAvz8IY0r4UvVraH9TS3qvhVo4Gsl7yxOoP7Qbz8zLvvL4IS6ivtjcVpBsDHKBXNm3S8vbglu05eVc-ilqN_vdXKDnPiJxyMc116JaLK5glb7VxJmrya65u459XvwFrE9BJLorhTVhQ6RYstydp9W14bj10yWcs8c4Iisic2ImWhvRSggiR6LzkBL7BHD8iQ00uVf-lNx4QnIPRK7o_kg1J3uQBNzGJ04SYBAQpzmDuQKd59dhoWZPGC9YIFTKzVCLQoyU6UDYX3JFUUk4Z83jssFDF1E8oDePQUcJ2ZOgxITDMTUTgKO4yKm26C5V0mKp9IE4QCkRcbugJiaGqGyqmtHKlFwrNfJVU4ayURoQbO89WxKkajj8ixC0uxp5ocaqwV0gnGhUVOKJSllXgM3L7eSAvmj07gtIwxbMnX__g3zNPYaX12L6L7q7vbw9hFQFUUFDHjqCSvY_VMYKUTJyYLfkNst3qwg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwEB1BkRAX9qWsRuKaNokTOzlCoSpLUQ-AEAei2LGhok0rSDjw9UycBpWKE7dEsaNEz_a88TzPAJxwrqXSwrUE08LytO9bseYJXgXC1eiLuWZroHvLOvfe1aP_OFXqy4j2peg30sGwkfZfjbZyPJTNSifW7HVbzC_SvPPmONHNeVjAOWuzKUfdLMIBWmZTKq0oEW7ZnlNU5qM4s9EG_0knZ1WRU2amvQJP1QeW6pK3Rp6Jhvyayd34rz9YheUJ-SSnZZM1mFPpOix2J-H1DXju9B7IZyzxzgBGZCHwxBWH9FOCTJHoIvUEvsEcQyIjTc7U4KWfDwn2QS8WzSDJRqQo9oCDmcRpQkwggpRnMTfhvn1x1-pYkwIM1hgnZmapRKBlS3SgbC64I6mknDLm8dhhoYqpn1AaxqGjhO3I0GNCoLubiMBR3GVU2nQLaukoVTtAnCAUyLzc0BMSXVY3VExp5UovFJr5KqnDcYVIhAO8iFrEqRrlHxHyFxd9UFx56rBdIhSNy0wcUYVnHfgv7H4aFMmzfz9BREwS7QkCu__ueQSLvfN2dHN5e70HS8ijglJBtg-17D1XB8hVMnFoRuU3D3ftQg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HPV+vaccination+coverage+in+the+federal+state+of+Belgium+according+to+regions+and+their+impact&rft.jtitle=Facts%2C+views+%26+vision+in+ObGyn&rft.au=Tjalma%2C+WAA&rft.au=Brasseur%2C+C&rft.au=Top%2C+G&rft.au=Ribesse%2C+N&rft.date=2018-06-01&rft.pub=Universa+Press&rft.issn=2032-0418&rft.volume=10&rft.issue=2&rft.spage=101&rft.epage=105&rft_id=info%3Apmid%2F31110649&rft.externalDBID=PMC6516187
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2032-0418&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2032-0418&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2032-0418&client=summon